TG Therapeutics: Trying To Fill The Gap Back To $20
tg therapeutics' q3'23 net sales of multiple sclerosis drug briumvi of $25.1m seemed to impress the market. J-code availability and increases in payor coverage aided sales of the drug. The company's anti-cd20 market in multiple sclerosis patients is large.
Seeking Alpha · 13h ago
Weekly Report: what happened at TGTX last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at TGTX last week (1113-1117)?
Weekly Report · 11/20 11:58
Weekly Report: what happened at TGTX last week (1106-1110)?
Weekly Report · 11/13 11:50
Tg Therapeutics Inc: Quarterly report
Press release · 11/07 04:02
Weekly Report: what happened at TGTX last week (1030-1103)?
Weekly Report · 11/06 11:57
Guru Fundamental Report for TGTX
NASDAQ · 11/02 20:07
Robust Financial Performance and Promising Sales Trajectory Drive Edward White’s Buy Rating for TG Therapeutics
TipRanks · 11/02 18:57
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Aurinia Pharmaceuticals (AUPH) and Cerevel Therapeutics Holdings (CERE)
TipRanks · 11/02 18:00
TG Therapeutics: Q3 Earnings Spike Hard To Explain Given Rival's Numbers
Seeking Alpha · 11/01 19:58
JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $23
Benzinga · 11/01 19:48
Notable Wednesday Option Activity: PLTR, EAT, TGTX
NASDAQ · 11/01 19:28
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cerevel Therapeutics Holdings (CERE) and TG Therapeutics (TGTX)
TipRanks · 11/01 18:50
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
Benzinga · 11/01 18:33
Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?
Benzinga · 11/01 18:11
Promising Outlook for TG Therapeutics: Strong Sales Performance and Growth Potential Backs Buy Rating
TipRanks · 11/01 18:07
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.